»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ w>Ft5"z
XoMgbDC
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 5VfpeA`
?q5HAIZ`
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© =
Q|s[F
1.Antigen presenting cell£¨APC£© gKIN* Od
2.Activation induced cell death£¨AICD£© WCp[6g&%O
3.Chemokine l?;ReK.r
4.Major histocompatibility complex£¨MHC£© n4ti{-^4|d
5.immunotolerance ^1--7#H
P|aSbsk:I<
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© >v%UV:7ap
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ *I9G"R8
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà qEjsAL
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ 2L 1Azx
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ MpJx>0j/J
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã / pR,l5
ZJ_P=
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© #8bI4J{dE
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ ]6HnK%
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ 6K9-n}z
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ a.AEF P4N
aK9zw
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ c-a;nAR
>[g'i+{
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 &44?k:
\N
g[lN
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ dtq]_HvTJ
1.Antigenic determinant k+cHx799
2.IgSF W-ECmw(
3.MBL;¾¶ {eo?vA8SE
4.chemokine cY*lsBo
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ GD .>u
6.TCR-CD3¸´ºÏÎï MMUw+jM4
7.FADD£¨Fas-associated protein with death domain£© }L*cP;m#
8.AIDS K3t^y`z
9.Tumor rejection antigen D$c4's`5
10.AICD _Msaub!N
E^.
=^bR
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ -f:uNF]Ls
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£©
:!Tb/1
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ ) 4'@=q
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ =>6'{32W_
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì z<mU$<
SSF4P&
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ W7"ks(
oa|nQ`[
Kq;Yb&
רҵ¿Î ÃâÒßѧ f+huhJS5
e
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê UpS`KgF"v
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell ZWSYh>"
5. Fc¦Å receptor 6. Cytokine ~$i36"
¶þ¡¢ ÎÊ´ðÌâ e;<=aa)}?
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 kGMI
?
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ Khxl'qj
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ m$:o+IH/
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 eUA6X
,I
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦ÓᣠQ': }'CI
-lm\~VZT3
[(Pm\o
0t1WvW
hX]vZR&R
n9Z|
69W6>
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ 0*q&)
.Kr?vD^nG
jnX9] PkJ
רҵ¿Î ÃâÒßѧ $z]gy]F
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê mh!;W=|/"
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen z)r)w?A
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin DQd~!21\|
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test GH![rK
9. Hybridoma technic 10.Mitogen C$xU!9K[+
11.Dentritic cell 12.Immunoproliferation GmB7@-[QA%
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ 52BlFBNV
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ _mKO4Atw
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠveg\A+:'
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ %8tlJQvu
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ [L8Bgw1
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¿ÊÔ·Ö±ð¼òÊöËüÃǵÄÖ÷ÒªÔÀí¡£
%lAJ]$m
NA>h$N
=9GL;z:R+
/Ws@YP
ZkkXITQkPM
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅËÄÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ |j$&W;yC
&!vJ3:
&xMR{:
רҵ¿Î ÃâÒßѧ &i4*tE3],
Ò»¡¢ Ãû´Ê½âÊÍ k5]s~*,0
1¡¢ ³Ù·¢Ðͱä̬·´Ó¦Tϸ°û 2¡¢ C1ÒÖÖÆÎï 2cr~/,YY
3¡¢ ¼¯Âä´Ì¼¤Òò×Ó 4¡¢ ¿¹ÔÌá³Ê×÷Óà NduvfA4
5¡¢ HIAÓë¼²²¡µÄ¹ØÁª 6¡¢ Ë«¹¦ÄÜ¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ \,i9 m9;y
¶þ¡¢ ÎÊ´ðÌâ T>e!DOW;
1¡¢ TÁÜ°Íϸ°û¾ßÓÐÄÄЩ±íÃæ±êÖ¾£¿ÊÔÊö¸÷±íÃæ±êÖ¾µÄÉúÎïѧ×÷Óü°/»òÒâÒå¡£ -$J\BkI
2¡¢ ÊÔÊöÒÆÖ²ÅųⷴӦµÄÃâÒßÓ¦´ð¹ý³Ì¼°²ÎÓëÅųⷴӦµÄÖÂÃôÁÜ°Íϸ°ûºÍЧӦÎïÖÊ¡£ \RyOexNZ
3¡¢ ºÎνϸ°ûÒò×Ó£¿¼òÊöÆ乲ͬÌص㼰ÓëÁÙ´²µÄ¹Øϵ¡£ }20
Q`?
4¡¢ ºÎνÁÜ°Íϸ°ûÔÓ½»Áö¼¼Êõ£¬ÊÔÊöÆäÔÀí¼°ÒâÒå¡£ at]=SA
5¡¢ ºÎνÉúÎïËØ-Ç׺ÍËØϵͳ£¿ÊÔÊöÆäÓ¦ÓÃÓÚÃâÒß±ê¼Ç¼¼ÊõµÄÔÀí£¬ÒÔABC·¨ÎªÀý˵Ã÷Ö®¡£ l^w=b~|7=
htX;"R&
W~
(@*H
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÎåÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ j h0``{
9W88_rE'e}
4^cDp!8
רҵ¿Î ÃâÒßѧ /8(c^
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê wZB:7E%
1¡¢ SmIg 2¡¢ Graft-versus-host reaction GVHR F5la:0fb
3¡¢ Immunocompent cell ICC 4¡¢ Tumor-associated antigen TAA VWDXEa9
5¡¢ Cytokine 6¡¢ Immune tolerance 7¡¢ Biological responsw modifier BRM D#Qfa!=g
¶þ¡¢ ÎÊ´ðÌâ vM
)2F
1¡¢ ÃâÒßϵͳÄÚÆðɱÉËЧӦµÄϸ°ûÓÐÄÄЩ£¿ÊÔ¼òÊöÆäɱÉËЧӦµÄÌص㡣 )c|S)iJ7=z
2¡¢ ºÎν¿¹ÌåµÄ¶àÑùÐÔ£¿¿¹ÌåµÄ¶àÑùÐÔ±íÏÖÔÚÄÄЩ·½Ã棿¼òÊö²úÉú¿¹Ìå¶àÑùÐÔµÄÔÀí¡£ @!k\Ivd
3¡¢ ÊÔÊö¢òÐÍÓë¢óÐͳ¬Ãô·´Ó¦·¢Éú»úÖƵÄÒìͬµã¡£ ?4>uGaU\
4¡¢ ºÎνMHC£¿ÊÔ¼òÊöÆ书ÄÜ¡£ EC9D.afy&
5¡¢ ºÎνÃâÒß±ê¼Ç¼¼Êõ£¿Ö÷ÒªÓÐÄļ¸ÀàÃâÒß±ê¼Ç¼¼Êõ£¬ÒÔø±ê¼Ç¼¼ÊõΪÀý¼òÊöÆäÖ÷ÒªÔÀí¡£ }xhat,9
YdsY2
BCnf'0q
55lL aus
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÁùÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ MV8Lk/zd?A
j5hM|\]
nT7{`aaQl
רҵ¿Î ÃâÒßѧ VrG4wLpLs
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê *Nfn6lVB
1. IgSF 2. Fc 3. Flow cytometry 4. Adhesion molecule t:A,pT3
5. Autogous mixed lymphoyte reaction RX]x3-
¶þ¡¢ ÎÊ´ðÌâ w8~J5XS
1. ÊÔÊöÍâÀ´TD¿¹Ô½øÈë»úÌåÓÕµ¼¿¹Ìå²úÉúµÄÈ«¹ý³Ì¡£ 5f54E|vD
2. ºÎνϸ°ûÒò×Ó£¿¼òÊöIL-2µÄ¼ì²â·½·¨¼°ÆäÔÀí¡£ p(2j7W-/
3. ¼òÊö¿¹¶ÀÌØÐÍÍøÂçµÄµ÷¿Ø×÷Óᣠ#
SmM5%
4. ÃâÒßÓ¦´ð¶Ô»úÌåÓкÎÀûº¦¹Øϵ£¿ C=L
XL1x2e
8ad
!.
^V^In-[!y:
-25#Vh
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÆßÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ @5gZK[?|I
(xU+Y1*g"%
(vIrXF5Dnj
רҵ¿Î ÃâÒßѧ vOYcS$,^X%
>/"XX,3
Q^Ln`zMe
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê FV/xp}nz
1. Idiotupe 2. Opsonization 3. Epitope 4. Immunologic tolerance :,
F^{
5. Delayed type hypersensitivity v)JQb-<
¶þ¡¢ ÎÊ´ðÌâ V>P\yr?
1. ÊÔÊö²¹Ì徵伤»î;¾¶ÓëÅÔ·¼¤»î;¾¶µÄÒìͬ¡£ bcpH|}[F)
2. ¼òÊö¿¹ÌåµÄ»ù±¾½á¹¹£¨ÒÔIgGΪÀý£©Ó빦ÄÜ¡£ /3%]Ggwe
3. ¼òÊöHLAÓëҽѧµÄ¹Øϵ¡£ |PN-,f{ -
4. ÊÔÊöµ¥ºË/¾ÞÊÉϸ°ûÔÚÃâÒßÓ¦´ðÖеÄ×÷Óᣠ6,G^iv6H
5. ¼òÊöÃâÒßÓ¦´ðÖи÷ÖÖÀàÐ͵Äϸ°û¶¾×÷Óᣠhk ./G'E
,WOF)
p!'wOThO`
=Ak>2
B^Ql[m&5+
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å°ËÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ mC~W/KReA
C>68$wd>
U7crbj;c)d
רҵ¿Î ÃâÒßѧ 4BEVG&Ks
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê SATZ!
1. hypersensitivity 2. cluster of differentiation 2L<TqC{,-
3. adhesion molecules 4. supper antigen 5. split tolerance 6%S>~L66
¶þ¡¢ ÎÊ´ðÌâ !W$Br\<
1. ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ÓµÄÖ÷ÒªÉúÎïѧ»îÐÔ¡£ wuYo@DDU#
2. ¼òÊöMHC¿¹ÔµÄ·Ö×ӽṹ¼°Æä×éÖ¯·Ö²¼¡£ 9: ~,TH
3. ÊÔÊöÐØÏÙÒÀÀµÐÔ¿¹ÔÒýÆðÌåÒºÃâÒßÓ¦´ðµÄÈ«¹ý³Ì£¨°üÀ¨³õ´ÎÃâÒßÓ¦´ðºÍÔÙ´ÎÃâÒßÓ¦´ð£©¡£ r)j#Skh].
4. Ϊʲô˵²¹Ì弤»î;¾¶Ö÷Òª²ÎÓëÌìÈ»ÃâÒߣ¿ÊÔÊö²¹ÌåÊÇÈçºÎ¾¹ýÅÔ·;¾¶¶ø±»¼¤»îµÄ¡£ dN*<dz+4r
5. Ϊʲô¿¹Ä³Ò»Ï¸°ûÒò×ÓÊÜÌåµÄµ¥¿Ë¡¿¹ÔÌ壬ÓбíÏÖ³öÊÜÌå·â±Õ×÷Ó㬶øÓеÄÔò±íÏÖ³öÊÜÌå´Ì¼¤×÷Óã¿ [/#n+sz.A
}= <!j5:
q',a7Tf:
Ne9
.wd
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ ]ipVN
רҵ¿Î ÃâÒßѧ =kc{ Q@Dk
Ò»¡¢ Ãû´Ê½âÊÍ
gSe{S
1. ¿¹ÔÐÔ 2. ÃâÒßÇòµ°°×³¬¼Ò×å 3. ¶ÀÌØÐÍ 4. ¿¹Ô¾ö¶¨×å (u'/tNGS
5. GVHR nVM`&azD
¶þ¡¢ ÎÊ´ðÌâ W@S9}+wl*
1. Á½ÖÖ²¹Ì弤»î;¾¶µÄµ÷½ÚÒò×ÓÓÐÄÄЩ£¿±È½ÏËüÃÇÁ½ÖÖ;¾¶ÖеÄ×÷ÓᣠRw\DJJrz
2. ¢òÐͳ¬Ãô·´Ó¦µÄ»úÀíÌصãÊÇʲô£¿¾Ù³öÈý¸ö¢òÐͳ¬Ãô·´Ó¦µÄÀý×Ó¡£ O0{v`|w9+
3. ÊÔÊöϸ°ûÒò×ÓµÄ×÷ÓÃÌص㡣 Z\7bp&&
4. Bcell½éµ¼µÄÌåÒºÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ 7r;A
wa
5. MPSµÄÃâÒßѧ¹¦ÄÜ¡£ O71rLk;
O0l;Qi
a$|u!_)!h
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ Z"^@B2v
68>zO%
^KF'/9S
רҵ¿Î ÃâÒßѧ +=8Po'E^!d
Ò»¡¢Ãû´Ê½âÊÍ NNdS:(
1. ÃâÒßÇòµ°°×µÄ¶ÀÌØÐÍ 2. 𤸽·Ö×Ó 3. ÃâÒßÇòµ°°×³¬¼Ò×å ~S6N'$
^
4. ¸ÉÈÅËØ 5. HLAµÄ¶à̬ÐÔ 6. ÐØÏÙÒÀÀµÐÔ¿¹Ô 7. ÃâÒßÄÍÊÜ R{B~No w3
8. ËÙ·¢Ðͳ¬Ãô·´Ó¦ 9. µ¥¿Ë¡¿¹Ìå 10. ²¹Ì徵伤»î;¾¶ <am7t[G."
11. »ìºÏÁÜ°Íϸ°û·´Ó¦ 12. ÓÐË¿·ÖÁÑ Uwk|M?94
Èý¡¢ ÎÊ´ðÌâ #*/h*GNMs
1. ÊÔ¼òÊö¾ÞÊÉϸ°ûÌá³ÊTD¿¹ÔµÄ¹ý³Ì¡£ C=cTj7Ub
2. ÊÔ¼òÊöÒÆÖ²ÎËÞÖ÷·´Ó¦µÄ·¢Éú»úÖÆ 6KG 63`aQ
3. ÊÔÊö²¹ÌåµÄÖ÷ÒªÉúÎïѧ×÷Óà AlxS?f2w
4. ÒÔIgGΪÀý£¬ÊÔÊöÃâÒßÇòµ°°×·Ö×ӵĻù±¾½á¹¹ [
_$$P*
5. ÊÔÊöTϸ°ûµÄÖ÷Òª±íÃæ±êÖ¾¼°¹¦ÄÜ U'G`Q0n
"-?Y UY`
A~V\r<N
j
%5gJ6>@6Z
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¾ÅÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ B;r$( 'UZ
`qz5rPyZ
_'U?!
רҵ¿Î ÃâÒßѧ |/;5|
z
Ò»¡¢Ãû´Ê½âÊÍ %U7f9
1. Ig¶ÀÌØÐÍ 2. SAg 3. 𤸽·Ö×Ó 4. CSF 5. IgSF 6. Tϸ°û»î»¯µÄ´Ì¼¤·Ö×Ó E |
7. HLAÓë¼²²¡µÄ¹ØÁª 8. ELISA 9. ÁÜ°Íϸ°ûµÄ±íÃæ±êÖ¾ #>B1$(@
Èý¡¢ ÎÊ´ðÌâ sLp
LY1X
1. ¼òÊöTÁÜ°Íϸ°ûµÄ·ÖÀ༰¹¦ÄÜ£¿ nF$)F?||
2. ¼òÊöHLAÍ»±äÌåµÄ»ùÒò×é³É¼°HLAµÄ¹¦ÄÜ£¿ \#,#_
3. ¼òÊö»úÌå¶ÔÍâÔ´ÐÔ¿¹Ô£¨ÒìÎԣ©µÄ´¦Àí£¬ÈçIgÌá³Ê¹ý³Ì£¿ 5q`)jd !*)
4. ¼òÊö²¹ÌåÁ½ÖÖ¼¤»î;¾¶µÄ»ù±¾¹ý³Ì£¬²¢±È½Ï¶þÕßÒìͬ£¿ NV4W2thYo
5. ¼òÊöAIDSÖÐCD4+ϸ°û¼õÉٵĻúÖÆ£¿ no6]{qn=6
L6=RD<~C
`Kw8rG\]:
=w$"wzc
rOr1H!
99Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ W?J[K;<
Ò»¡¢Ãû´Ê½âÊÍ B2qq C-hw?
2¡¢ HLAµÄ¶à̬ÐÔ 3¡¢ 𤸽·Ö×Ó 4¡¢ ¶ÀÌØÐÍ 5¡¢ ¿¹ÔëÄתÔËÎï |Umfq:W`y_
6¡¢ Ig³¬¼Ò×å 7¡¢ µòÍö 8¡¢ ÓÐË¿·ÖÁÑÔ 9¡¢ CD4·Ö×Ó 6ilC
#yyp
10¡¢ ³¬Ãô·´Ó¦ 11¡¢ ×ÔÉíÃâÒß²¡ Mqf}Aiqk;
¶þ¡¢ ÎÊ´ðÌâ 8yz((?LrDh
1¡¢ ÊÔÊöÍâÔ´ÐÔ¿¹ÔºÍÄÚÔ´ÐÔ¿¹ÔÌá³ÊµÄ¹ý³Ì¡£ (DP9
& b
2¡¢ ÊÔÊöBϸ°û½éµ¼µÄÔÙ´ÎÃâÒßÓ¦´ðµÄ¹ý³Ì¡£ 4U;XqUY
/
3¡¢ ÊÔÊö·Ö×ÓˮƽµÄÃâÒßµ÷½Ú¡£ $RNUr
\9A
4¡¢ ÊÔÊö»ñµÃÐÔÃâÒßȱÏÝ×ÛºÏÕ÷£¨AIDS£©µÄ·¢²¡»úÖÆ¡£ gIM'bA<~
}cK~=@7tK
2000Äê˶ʿÑо¿ÉúÃâÒßѧÊÔÌâ 6 %k
+0\d
Ò»¡¢ Ãû´Ê½âÊÍ 7O9hn2?e
1¡¢ µ÷Àí×÷Óà 2¡¢ 𤸽·Ö×Ó 3¡¢ ³¬¿¹Ô 4¡¢ ÃâÒßȱÏݲ¡ C9Z\G 3
5¡¢ FasÓëFasL 6¡¢ µ¥¿Ë¡¿¹Ìå 7¡¢ ÃâÒßÄÍÊÜ J[Yg]6
8¡¢ ÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£© 9¡¢ Ö×ÁöÏà¹Ø¿¹Ô£¨TAA£© ck_fEF
10¡¢ ÒõÐÔÑ¡Ôñ grxl{uIC8
¶þ¡¢ ÎÊ´ðÌâ eGSp(o5 6
1¡¢ ºÎνϸ°ûÒò×Ó£¿ÊÔÊöϸ°ûÒò×ӵĹ²Í¬Ìص㣿 ]baaOD$Z
2¡¢ ºÎνAPC¼°ÆäÖÖÀࣿ¼òÊöÍâÔ´ÐÔ¿¹ÔµÄÈÜøÌåÌá³Ê;¾¶£¿ 27 145
3¡¢ ¼òÊöϸ°ûÃâÒßÓ¦´ðµÄÁ½ÀàЧӦϸ°ûµÄЧӦ»úÖÆ£¿Ï¸°ûÃâÒßµÄÉúÎïѧÒâÒ壿 5+/b$mHZX
4¡¢ ºÎνMHC£¿¼òÊöMHCµÄ¹¦ÄÜ£¿ #DK3p0d
5¡¢ ºÎν×ÔÉíÃâÒß²¡£¿¼òÊö×ÔÉíÃâÒß²¡µÄ×éÖ¯ËðÉË»úÖÆ£¿. >AzWM
.r
Jg|cvu-+
z1'FmwT
l/png:
ͬ¼ÃÒ½¿Æ´óѧ2000Äê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ {`H<=h__
8 ih;#I=q
mYh5#E41J
רҵ¿Î ÃâÒßѧ 9XoQO 9*Q
Ò»¡¢½«ÏÂÁÐÓ¢Óïµ¥´Ê·Òë³ÉÖÐÎIJ¢Ãû´Ê½âÊÍ M6jp1:ZH2q
1. Cytokines 2. adhesion molecules 3. graft versus host reaction 2\nN4WL
5.
4. immunologic tolerance 5. Opsonization O b8B
Èý¡¢ ÎÊ´ðÌâ
gmRT1T
1. ʲôÊÇMHC£¿ÊÔÊöMHC-¢òÀà·Ö×ӵĽṹ¡¢¸÷²¿Î»¹¦ÄÜ£¬MHC-¢òÀà·Ö×ÓµÄ×éÖ¯·Ö²¼¼°ÆäÃâÒßѧ×÷ÓᣠnJleef9
2. ÓÐÄÄÈý´ú¿¹Ì壿ÊÔÊö¿¹Ì壨IgG£©µÄ»ù±¾½á¹¹¡¢¸÷²¿Î»¹¦Äܼ°ÕâÈý´ú¿¹ÌåµÄÌØÐÔ¡£ v.
Xoq
3. ʲôÊÇ×ÔÉíÃâÒß²¡£¿ÊÔÊöÆä·¢²¡»úÖÆ¡£ kYxl1nv
4. ÃâÒßϵͳɱÉË°Ðϸ°ûµÄ·½Ê½¼°ÏàӦϸ°ûºÍ·Ö×ÓÓÐÄÄЩ£¿ÊÔÊöTc½éµ¼µÄϸ°ûÃâÒßÓ¦´ð¡£ )_77>f%
5. »úÌåµÄÃâÒßϵͳΪʲô¿ÉÒÔʶ±ð×Ô¼ººÍÒ켺£¿ÆäÖ÷Òª»úÖÆÊÇʲô£¿ H\fcY p6
]^:hyOK
n$XdSh/
aXdf>2c{JD
wfxOx$]zK
=n-z;/NL
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ 4E=0qbt8
?fK^&6pI
JbE?a[Eg?
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧרҵ¿Î¿¼ÊÔÊÔÌâ +
<Z+-
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ oi2J:Y4
Ò»¡¢ ½âÊÍÏÂÁÐÃû´Ê `gBD_0<T7
1. C3b½éµ¼µÄµ÷Àí×÷Óà 2.Tϸ°û¼¤»îµÄµÚ¶þÐźÅ3.Th1ϸ°û 4.HLAµÄ¶à̬ÐÔ R?
O-x9
5.C1ÒÖÖÆÎï 6.TCR¦Ã¦ÄTϸ°û7.³Ù·¢Ðͳ¬Ãô·´Ó¦ 8.Ç÷»¯ÐÔϸ°ûÒò×Ó9.ÃâÒßÇòµ°°×µÄÀà±ðת»¯ 10.ÔìѪ¸Éϸ°û +}Xr1fr{jw
11.»î»¯ÓÕµ¼µÄϸ°ûËÀÍö C"w,('~@kW
¶þ¡¢ Çë»Ø´ðÏÂÁÐÎÊ´ð x6LjcRS|
1. ºÎνµ¥¿Ë¡¿¹Ì壬¼òÊöÆäÖƱ¸ÔÀí¡£ R0%?:!
F
2. ¼òÊöTϸ°ûÔÚÐØÏÙÄڵķ¢Óý¹ý³Ì¡£ I(pb-oY3!I
3. ÃâÒßϸ°û±íÃæÖ÷ÒªÓÐÄļ¸Àà±íÃ濹ԺͱíÃæÊÜÌ壬¼òÊö¸÷Àà·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡££¨HLA¡¢CD¡¢AM¡¢CKR¡¢CR¡¢MitogenR¡¢TCR¡¢BCR¡¢FcR£© 2Ok?@ZdjA{
4. ÊԱȽÏTCR¸´ºÏÌåºÍBCR¸´ºÏÌå½á¹¹Ó빦ÄܵÄÒìͬ¡£ 8QV t,
'I
5. ÊԱȽϳ¬¿¹ÔÓëÆÕͨ¿¹ÔµÄÒìͬ¡£ m$,,YKhh
2G?$X?
@7-=zt+f
rJu[N(2k
Gz?2b#7v
`\!X}xiWd
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ "3SWO3-x
2001ÄêÕÐÊÕ˶ʿÑо¿ÉúÈëѧµ¥¶À¿¼ÊÔÊÔÌâ q/$GE,"
¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ rj 3YTu`
\m f*ge\
Ò»¡¢ Ãû´Ê½âÊÍ V$(/0mQV(
1. ¿¹Ô³ÊµÝ 2. µ÷Àí×÷Óà 3. ³Áµí·´Ó¦ 4. ×ÔÉíÃâÒß lV\lj@
5. GVHR 6. ÔìѪ¸Éϸ°û 7. ¿Ë¡ѡÔñѧ˵ 8. Ir»ùÒò r'p =`2=
9. ³¬Ãô·´Ó¦ 10. ³¬¿¹Ô O+_N!/
¶þ¡¢ÎÊ´ðÌâ 77*qkKr
11. ¼òÊö²¹ÌåµÄÅÔ·¼¤»î;¾¶ >Q=Ukn;k
12. ¼òÊöT¡¢Bϸ°ûÌØÕ÷µÄ²îÒì dv, C6t2
13. ¼òÊöT¡¢Bϸ°û¿¹Ô¾ö¶¨´ØµÄ²îÒì 3;-^YG
14. ΪʲôÃâÒßÇòµ°°×¾ßÓп¹ÔÐÔ£¿ÊÔÊöÃâÒßÇòµ°°×µÄ¿¹ÔÐÔ¡£ zmiZ]uq
15. ʲôÊÇÖ×Áö¿¹Ô£¿ÊÔÊö»úÌåÕë¶ÔÖ×Áö¿¹Ô²úÉú¿¹Ö×ÁöÃâÒßÓ¦´ðµÄ»úÖÆ¡£ W`rMtzL5
MS*G-C